High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients

Radiation Oncology

Nikolaos Zamboglou³  Markus Ratka³  Dimos Baltas²  Natasa Milickovic²  Georgios Chatzikonstantinou³  Ulf W Tunn¹  Nikolaos Tselis³ 

[1] Department of Urology, Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany;Department of Medical Physics and Engineering, Klinikum Offenbach, Starkenburgring 66,63069, Offenbach, Germany;Department of Radiation Oncology, Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Germany

关键词: Monotherapy;    Iridium;    High dose rate;    Brachytherapy;    Prostate cancer;   

Others  :  1153980
DOI  :  10.1186/1748-717X-8-115

 received in 2013-02-02, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

Background

To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically localised prostate cancer.

Methods

Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised prostate cancer were treated with transrectal ultrasound guided high dose rate brachytherapy. The prescribed dose was 38.0 Gy in four fractions (two implants of two fractions each of 9.5 Gy with an interval of 14 days between the implants) delivered to an intraoperative transrectal ultrasound real-time defined planning treatment volume. Biochemical failure was defined according to the Phoenix Consensus and toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 3.

Results

The median follow-up time was 59.3 months. The 36 and 60 month biochemical control and metastasis-free survival rates were respectively 98%, 94% and 99%, 98%. Toxicity was scored per event with 4.8% acute Grade 3 genitourinary and no acute Grade 3 gastrointestinal toxicity. Late Grade 3 genitourinary and gastrointestinal toxicity were respectively 3.4% and 1.4%. No instances of Grade 4 or greater acute or late adverse events were reported.

Conclusions

Our results confirm high dose rate brachytherapy as safe and effective monotherapy for clinically organ-confined prostate cancer.

【 授权许可】

   
2013 Tselis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mark R, Anderson P, Akins R: Interstitial high-dose-rate brachytherapy as monotherapy for early stage prostate cancer: Median 8-year results in 301 patients. [Abstract]. Brachytherapy 2010, 9:76.
• [2]Yoshioka Y, Konishi K, Sumida I: Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011, 80:469-75.
• [3]Hoskin P, Rojas A, Lowe G: High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012, 82:1376-84.
• [4]Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P: A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:441-46.
• [5]Demanes DJ, Martinez AA, Ghilezan M: High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-92.
• [6]Barkati M, Williams SG, Foroudi F: High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys 2012, 82:1889-96.
• [7]Grills IS, Martinez AA, Hollander M: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-104.
• [8]Rogers CL, Alder SC, Rogers RL: High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012, 187:109-16.
• [9]Potters L, Morgenstern C, Calugaru E: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562-66.
• [10]Battermann JJ, Boon TA, Moerland MA: Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004, 71:23-28.
• [11]Zelefsky MJ, Kuban DA, Levy LB: Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-33.
• [12]Pollack A, Zagars GK, Starkschall G: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-105.
• [13]Zelefsky MJ, Yamada Y, Fuks Z: Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71:1028-33.
• [14]Dearnaley DP, Sydes MR, Graham JD: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-87.
• [15]D'Amico AV, Whittington R, Malkowicz SB: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281-86.
• [16]Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS: High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33:481-88.
• [17]Zamboglou N, Tselis N, Baltas D: High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013, 85:672-8.
• [18]Zelefsky MJ, Leibel SA, Gaudin PB: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491-500.
• [19]Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G: Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 2001, 49:61-69.
• [20]Roach M, Hanks G, Thames H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-74.
• [21]Skazikis G, Kurek R, Baltas D: Acute toxicity of HDR-brachytherapy as monotherapy for low-risk cancer: Analysis of 297 patients treated with two different fractionation schemes. [Abstract]. Strahlenther Onkol 2007, 183:125. Sondernr 1
• [22]Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
• [23]Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001, 50:1021-31.
• [24]Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-101.
• [25]Milickovic N, Mavroidis P, Tselis N: 4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U/S-based prostate HDR brachytherapy treatment delivery. Med Phys 2011, 38:4982-93.
• [26]Ghadjar P, Keller T, Rentsch CA: Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
• [27]Prada PJ, Jimenez I, González-Suárez H, Fernández J, Cuervo-Arango C, Mendez L: High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012, 11:105-10.
• [28]Yamada Y, Rogers L, Demanes DJ: American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012, 11:20-32.
• [29]Peddada AV, Jennings SB, Faricy PO, Walsh RA, White GA, Monroe AT: Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 2007, 178:1963-67.
• [30]Monroe AT, Faricy PO, Jennings SB, Biggers RD, Gibbs GL, Peddada AV: High-dose-rate brachytherapy for large prostate volumes (≥50cc) - uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 2008, 7:7-11.